Clinicalobservationofcapecitabinemonotherapyinelderlypatientswithadvancedbreastcancer
摘要: ObjectiveTheaimofthestudywastoevaluatethesafetyandefficacyofcapecitabinemono-chemotherapyinelderlypatientswithadvancedbreastcancer.MethodsThedatafrom36casesofcapecitabinemonotherapyinelderlypatientswithadvancedbreastcancerwereretrospectivelyanalyzed.Oraladministrationofcapecitabine2000mg/m2twicedaily(D1–14)for21daysconstitutedacycle.Theeffectofthediseaseandmainadversereactionswereevaluatedevery2cycles.ResultsThedatafrom36elderlypatientswerestudied.Themediannumberofchemotherapycycleswas4.Thetotaleffectiveratewas30.6%(11/36)andthediseasecontrolratewas72.2%(26/36).Thenumberofpatientswithclinicalcompleteremissionwas2,clinicalpartialresponsewas9,stablediseasewas15,andprogressivediseasewas10.Wheretreatmentwaseffective,themediantimetoprogressionwas6monthsandthemedianoverallsurvivalwas9.5months.Themainadverseeventsweregastrointestinalreactions,bonemarrowsuppression,andoralmucositis;mostofthereactionsweregrade1to2.Grade3to4adversereactionsincludedgranulocytopeniain2patients(12.5%)andhand-footsyndromein1patient(6.7%).ConclusionCapecitabinemonotherapywaseffectiveincontrollingdiseaseprogression,andadversereactionsweretoleratedbyelderlypatientswithadvancedbreastcancer. ...
(共4頁(yè))
開(kāi)通會(huì)員,享受整站包年服務(wù)